Company intelligence / Profile preview

botiss biomaterials

Ownership: Private
Employees: ~120
Development stage: Commercial

Overview

botiss biomaterials' products are widely used globally with proven safety and efficacy supported by numerous preclinical and clinical studies. Their solutions have been applied to hundreds of thousands of patients worldwide for various dental regenerative indications.

Therapeutic areas: Other
Modalities: Bone graft substitute (bovine-derived)Allogeneic bone graftsSynthetic bone substitutes (biphasic calcium phosphate)Collagen-based membranes and matricesMagnesium-based resorbable devices
Industry: Surgical Medical Devices

Partnerships

Meisinger USA – distribution partnership for US marketCells+Tissuebank Austria – processing partner for allograftsCollaborations with global academic research institutes and opinion leaders

Beyond the preview

Go deeper on botiss biomaterials.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on botiss biomaterials.

Explore the full profile